- Summits
- Sponsorship
- Media Opportunities
- News
- About
BioAro’s UAE subsidiary has received official approval for a Drug Store (Medical Warehouse) License in the United Arab Emirates, authorizing the company to import, store, and distribute medicines, medical devices, and healthcare products across the country. The development strengthens the company’s operational footprint in the region and creates new entry opportunities for global health and MedTech companies seeking structured access to the UAE market.
In the UAE, securing product approval from the Ministry of Health and Prevention (MOHAP) is only part of the regulatory journey. While companies may obtain MOHAP approvals for medicines, medical devices, and medical supplies, regulatory clearance alone does not permit direct importation, warehousing, or commercial distribution within the country. These activities must be conducted through a licensed Drug Store entity authorized to manage compliant importation, customs clearance, storage, and nationwide distribution.
With its newly secured license, BioAro can now act as that licensed infrastructure partner.
The Drug Store license authorizes BioAro to import regulated medical products, clear shipments through UAE customs, and provide compliant warehousing, including temperature-controlled storage where required. The company is also authorized to maintain traceability, pharmacovigilance, and quality systems aligned with Good Distribution Practice standards, and to distribute products to hospitals, clinics, and pharmacies across the UAE.
For international startups, pharmaceutical manufacturers, nutraceutical brands, and medical device companies, the UAE represents a strategic gateway market. However, regulatory navigation, customs procedures, pricing controls, labeling requirements, and operational setup can significantly delay commercialization.
Through its licensed Drug Store platform, BioAro now offers integrated support designed to reduce time to market while eliminating the need for foreign companies to establish their own local warehousing infrastructure. The structure ensures full regulatory compliance while allowing companies to focus on product positioning and growth.
In parallel, Kapoor Wealth Partners provides regulatory advisory and structured market entry support. The firm assists companies with product classification, technical file and dossier preparation, submission management, health authority coordination, and post-approval compliance strategy. Together, the combined capabilities offer a pathway that spans regulatory clearance through to compliant importation, storage, and nationwide distribution.
The license follows BioAro’s recent UAE approvals for its proprietary longevity product portfolio, including LONgevity+, CellOmega+, and CreaGen. These products include age- and sex-specific compositions incorporating targeted micronutrients and required adherence to UAE regulatory, labeling, and compliance standards. Securing those approvals validated BioAro’s framework within the UAE system and positioned the company for broader operational expansion.
With the Drug Store license now in place, BioAro transitions from being solely a product registrant to operating as a fully licensed healthcare distribution platform capable of supporting third-party manufacturers and innovators entering the UAE market.
Dr. Anmol S. Kapoor, Founder of BioAro, stated: “Securing our Drug Store license in the UAE is a critical step in building compliant healthcare infrastructure in the region. Many companies achieve MOHAP product approvals but lack the licensed entity required to import, warehouse, and distribute within the country. By combining regulatory advisory through Kapoor Wealth Partners with licensed distribution capabilities under BioAro, we are creating a seamless pathway for global health innovators to responsibly and efficiently enter the UAE market. Our goal is not only to introduce products, but to establish long-term, compliant, and scalable healthcare operations within the Emirates.”
Ms. Ruchi Bindra, Director, Communications and Regulatory Partnerships at Kapoor Wealth Partners in Abu Dhabi, added: “The UAE regulatory environment is robust and structured to ensure patient safety and product quality. For international companies, understanding classification pathways, documentation standards, pricing frameworks, and authority engagement protocols is essential. Kapoor Wealth Partners works closely with health authorities to guide companies through product registration and approval processes, while BioAro’s licensed Drug Store capability ensures those approvals translate into real commercial execution. Together, we provide clarity, compliance, and continuity from regulatory strategy to distribution.”
As the UAE continues to invest in healthcare innovation, preventive medicine, biotechnology, and advanced life sciences as part of its broader economic diversification strategy, licensed supply chain infrastructure plays an increasingly important role. BioAro’s expanded authorization aligns with national priorities focused on strengthening medical supply chain resilience and enabling responsible access to advanced therapeutics and health technologies.
Following the success of its flagship event in Dubai earlier in February, MedTech World is now heading to Florida for its next major edition. The North America event in West Palm Beach will bring together founders, investors, healthcare leaders, and policymakers to explore commercialization pathways, cross-border collaboration, and capital deployment in MedTech.
If you are looking to be part of this milestone North America edition, you can engage in ways that align with your goals:
